STOCK TITAN

IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

IDEAYA Biosciences (Nasdaq: IDYA) outlined IDE849 registration plans for previously treated neuroendocrine carcinomas following a Type C FDA meeting.

The company plans an approximately 90-patient gastroenteropancreatic neuroendocrine carcinoma cohort targeting potential accelerated approval, using confirmed response rate assessed by blinded independent review. A planned randomized Phase 3 trial across multiple neuroendocrine carcinoma subtypes would assess progression-free survival for accelerated approval and overall survival for full approval. IDEAYA targets starting both studies and a Phase 3 trial after Imdelltra in extensive-stage small cell lung cancer by year-end 2026.

Partner Phase 1 data showed a 52.6% response rate among 19 patients, with 36.8% confirmed responses. In the separate global Phase 1/2 trial, severe treatment-related adverse event rates were 5% and 22.2% at the respective expansion doses.

Loading...
Loading translation...
8 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Approximately 90-patient cohort planned in previously treated gastroenteropancreatic neuroendocrine carcinoma to support potential accelerated approval.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Randomized Phase 3 trial planned across neuroendocrine carcinoma subtypes, targeting full approval and additional subtype approvals.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Post-Imdelltra Phase 3 trial in extensive-stage small cell lung cancer targeted to start by year-end 2026.
  • Minor pointFirst-line combination study designs remain under evaluation for extensive-stage small cell lung cancer.
  • Minor pointPhase 1 response rate was 52.6% (10/19); confirmed response rate was 36.8% (7/19) in neuroendocrine carcinomas.
3 minor points
  • Minor pointDisease control rate was 84.2% (16/19) among Phase 1 patients with neuroendocrine carcinomas.
  • Minor pointMedian progression-free survival was 7.0 months in Phase 1 neuroendocrine carcinoma patients.
  • Minor pointEstimated nine-month overall survival was 82.4% in Phase 1 neuroendocrine carcinoma patients.

Negative

  • Minor pointGrade ≥3 treatment-related adverse events occurred in 5% (1/20) at 2.4 mg/kg and 22.2% (4/18) at 3.5 mg/kg.
  • Minor pointInterstitial lung disease occurred at Grade 1–2 in 6.6% (8/122) and Grade ≥3 in 0.8% (1/122) in Phase 1.

News Explained

The company reports that the FDA Type C meeting on IDE849 registrational designs was successful and completed; the cohort and trials are still planned, not initiated, so this updates design alignment rather than trial initiation or approval.

Key Figures

Extension cohort: Approximately 90 patients Registrational trial initiation: By the end of 2026 ORR: 52.6% (10/19) +5 more
Extension cohort
Approximately 90 patients
Planned refractory GEP-NEC cohort
Registrational trial initiation
By the end of 2026
Planned NEC trials and potential single-arm extension cohort
ORR
52.6% (10/19)
IDE849 Phase 1/2 data in NEC
Confirmed ORR
36.8% (7/19)
IDE849 Phase 1/2 data in NEC
Median PFS
7.0 months
IDE849 Phase 1/2 data in NEC
Nine-month OS rate
Estimated 82.4%
IDE849 Phase 1/2 data in 2L+ NEC
Grade ≥3 TRAE rate
5% (1/20)
2.4 mg/kg expansion dose
Grade ≥3 TRAE rate
22.2% (4/18)
3.5 mg/kg expansion dose

Previous Clinical trial Reports

1 past event · Latest: Oct 23
Same Type 1 event
  1. Oct 23

    IDE849 Phase 1 data

    24h Move
    -3.9%

    Updated IDE849 Phase 1 data included 36.8% confirmed response among 19 neuroendocrine carcinoma patients.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

antibody drug conjugate, blinded independent central review, overall response rate, progression free survival, +2 more
6 terms
antibody drug conjugate medical
"Topo-I-payload antibody drug conjugate (ADC)"
An antibody drug conjugate is a targeted medical treatment that combines a special antibody with a powerful drug, allowing precise delivery of the medicine directly to cancer cells or other harmful cells in the body. For investors, it represents a sophisticated approach to therapy that could improve treatment effectiveness and reduce side effects, potentially leading to significant growth opportunities in the biotech and pharmaceutical sectors.
blinded independent central review medical
"assessed by blinded independent central review (BICR)"
Blinded independent central review is a quality-control step in clinical trials where outside medical experts, who do not know which patients received the experimental therapy, re-examine key measurements (like scans or lab results) to prevent bias. Think of it as neutral referees watching game footage without knowing the teams, which gives investors greater confidence that the trial results are fair, more reliable for regulators, and less likely to be overturned or disputed.
overall response rate medical
"confirmed overall response rate (ORR)"
Overall response rate is the percentage of patients in a clinical study whose measurable disease shrinks or disappears after receiving a treatment. Investors watch it like a product’s “hit rate” because higher response rates can signal a drug’s effectiveness, boost chances of regulatory approval and market demand, and affect a company’s future revenue prospects, similar to how a higher batting average suggests a more reliable player.
progression free survival medical
"primary endpoints of progression free survival (PFS)"
Progression free survival is the length of time during and after a treatment when a disease, such as cancer, does not get worse or spread. It is an important measure because longer periods of stability can indicate that a treatment is effectively controlling the condition. For investors, it provides insight into the potential durability and success of a therapy or medication.
overall survival medical
"and overall survival (OS) for full approval"
Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.
interstitial lung disease medical
"interstitial lung disease (ILD) observed in 6.6%"
A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint
  • Randomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval, with OS as the primary endpoint
  • IDE849 has demonstrated a 52.6% ORR (10/19), median PFS of 7.0 months, and an estimated 9-month OS rate of 82.4% in 2L+ NEC
  • Global Phase 1/2 trial of IDE849 has shown a Grade ≥3 TRAE rate of 5% (1/20) and 22.2% (4/18) at the 2.4 mg/kg and 3.5 mg/kg expansion doses, respectively
  • IDEAYA is targeting to initiate two randomized Phase 3 registrational trials in the refractory NEC and post-Imdelltra ES-SCLC settings, and a potential registration-enabling single-arm extension cohort in refractory GEP-NEC, by the end of 2026

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of transformative therapies to address unmet medical needs in cancer, today announced its registrational strategy for IDE849, a potential best-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC), in previously treated (2L+) neuroendocrine carcinomas (NEC).  IDEAYA is planning to initiate registrational trials in both previously treated NEC and extensive-stage small cell lung cancer (ES-SCLC) by the end of the year. 

"NEC is an aggressive disease with limited treatment options after first-line platinum-based chemotherapy.  Our recent IDE849 data presented at ESMO in refractory NEC provides strong support for the clinical benefit that a DLL3-targeted ADC may offer for patients with this devastating disease," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences. "In light of the fast-evolving landscape of DLL3-targeting agents we have completed two Type C meetings with the U.S. FDA and leading clinical investigators globally to align on the study designs for our registrational trials in both refractory NEC and ES-SCLC, including for accelerated approval, to ensure IDE849 is well positioned to become a viable new potential treatment option for patients with these difficult to treat cancers."

Registrational Strategy for IDE849 in NEC

Following a successful Type C meeting with the U.S. Food and Drug Administration (FDA) IDEAYA plans to advance a registrational development program for IDE849 in neuroendocrine carcinoma (NEC) by the end of 2026. The company intends to initiate a single-arm extension cohort within its ongoing Phase 1/2 clinical trial, enrolling approximately 90 previously treated patients with gastroenteropancreatic NEC (GEP-NEC). The cohort is intended to support a potential accelerated approval application, with a primary endpoint of confirmed overall response rate (ORR) assessed by blinded independent central review (BICR), supported by duration of response. Based on data from their ongoing global Phase 1/2 dose escalation and expansion trial, IDEAYA intends to evaluate IDE849 at doses of 2.4 mg/kg and 3.5 mg/kg IV dosed once every three weeks (Q3W).  If successful, this single-arm extension cohort could support an accelerated approval for IDE849 in GEP-NEC. 

IDEAYA also plans to submit a protocol for a randomized, confirmatory Phase 3 trial of IDE849 in multiple NEC subtypes, including GEP-NEC and large cell NEC (LC-NEC), to support trial initiation by the end of the year.  The randomized Phase 3 trial is intended to verify clinical benefit and support conversion of the potential accelerated approval to full approval in GEP-NEC and to expand approval in additional NEC subtypes, including LC-NEC, with the primary endpoints of progression free survival (PFS) for accelerated approval and overall survival (OS) for full approval.  IDEAYA expects this trial to be well underway to fully enrolled at the time of the anticipated topline results from the single-arm trial.

In ES-SCLC, IDEAYA is on track to initiate a randomized Phase 3 registrational trial of IDE849 monotherapy in the post-Imdelltra setting by the end of the year, while continuing to evaluate several potential first-line study designs based on rational combinations that could offer differentiated safety and efficacy compared to current treatment standards.

Clinical Data Supporting the NEC Registrational Strategy

In October 2026, IDEAYA's partner Hengrui presented updated Phase 1 results for IDE849 at doses ≥1.8 mg/kg IV Q3W at the European Society for Medical Oncology (ESMO) Congress. Among 19 patients with NECs, ORR was 52.6% (10/19; 95% CI: 28.9–75.6), confirmed ORR was 36.8% (7/19; 95% CI: 16.3–61.6), and disease control rate was 84.2% (16/19).  The median PFS was 7.0-months and the nine-month OS rate was 82.4%, complementing the promising clinical efficacy also reported from refractory SCLC patients in the trial.  Across a total of 122 patients in the trial, IDE849 continued to demonstrate a favorable safety profile, with Grade 1-2 interstitial lung disease (ILD) observed in 6.6% (n=8) of patients and Grade ≥3 ILD in 0.8% (n=1).  IDEAYA is evaluating IDE849 in an ongoing Phase 1/2 global trial in both ES-SCLC and NEC, where a Grade ≥3 TRAE rate of 5% (1/20) at 2.4 mg/kg and 22.2% (4/18) at 3.5 mg/kg expansion doses has been observed.

About IDE849

IDE849 (SHR-4849) is an investigational ADC that combines a humanized anti-DLL3 IgG1 antibody with a TOP1 inhibitor payload through a cleavable linker. The program is designed to target DLL3-expressing cancers, including ES-SCLC and other NECs. In December 2024, IDEAYA licensed the global development and commercialization rights to IDE849 outside of Greater China from Hengrui.

About NECs

High DLL3 expression has been reported across multiple solid tumor subtypes of NECs that remain areas of high unmet medical need with few treatment options, including GEP-NEC and large cell neuroendocrine carcinoma (LC-NEC).  The projected annual incidence of GEP-NEC and LC-NEC globally (excluding China) in the metastatic setting is projected to be approximately 40,000 patients and 30,000 patients, respectively.  In the major market countries of the United States, EU5, and Japan, the annual incidence of metastatic GEP-NEC and LC-NEC is projected to be approximately 7,000 patients and 8,000 patients, respectively.  Multiple other subtypes of NECs also have high DLL3 expression, including bladder and cervical, among others.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding IDEAYA's registrational strategy for IDE849 in NEC and ES-SCLC, including the planned expansion of Arm 5 of the Phase 1 study, the planned randomized confirmatory Phase 3 trial, and trial design, endpoints, patient population, enrollment, comparator, timing and dose selection; the potential for accelerated and full approval; and the potential clinical profile of IDE849. Such statements are subject to risks and uncertainties, including that the FDA's feedback from regulatory meetings is preliminary and nonbinding, and the FDA may subsequently require modifications to the proposed trial designs, endpoints, patient population, statistical analysis plan or regulatory strategy, or require additional data or trials; the FDA may determine that a single-arm study or overall response rate does not support accelerated approval, may require that a confirmatory trial be underway prior to approval, or that the trial results do not verify clinical benefit or support full approval; IDEAYA may experience delays in selecting a recommended Phase 3 dose or in initiating, enrolling, conducting or completing clinical trials; early clinical results, including those from a Phase 1 trial conducted by Hengrui in China, may not be reproduced in later trials; and other risks described in IDEAYA's filings with the Securities and Exchange Commission. IDEAYA undertakes no obligation to update forward-looking statements except as required by law.

Investor and Media Contact

IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-successful-us-fda-type-c-meeting-on-phase-23-registrational-trial-designs-to-support-potential-accelerated-and-full-approval-for-ide849-a-potential-best-in-class-dll3-top1-adc-in-neuroendocrine-carc-302939594.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is IDEAYA's IDE849 accelerated approval strategy in neuroendocrine carcinoma?

IDEAYA plans an approximately 90-patient single-arm extension cohort in previously treated gastroenteropancreatic neuroendocrine carcinoma to support potential accelerated approval. The primary endpoint is confirmed overall response rate assessed by blinded independent central review, supported by how long responses last.

What will IDEAYA's randomized IDE849 Phase 3 neuroendocrine carcinoma trial measure?

The planned randomized Phase 3 trial will use progression-free survival for accelerated approval and overall survival for full approval. It will include gastroenteropancreatic and large cell neuroendocrine carcinomas. IDEAYA expects the trial to be well underway to fully enrolled when anticipated single-arm trial topline results become available.

What IDE849 doses does IDEAYA plan to evaluate in the neuroendocrine carcinoma extension cohort?

IDEAYA intends to evaluate 2.4 mg/kg and 3.5 mg/kg intravenously once every three weeks in the extension cohort. The dose selection draws on its ongoing global Phase 1/2 dose escalation and expansion trial.

Keep reading